Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Anthracycline compounds are major culprits in chemotherapy-induced cardiotoxicity, which is the chief limiting factor in delivering optimal chemotherapy to cancer patients. Although extensive efforts have been devoted to identifying strategies to prevent anthracycline-induced cardiotoxicity, there is little consensus regarding the best approach. Recent advances in basic mechanisms of anthracycline-induced cardiotoxicity provided a unified theory to explain the old reactive-oxygen species hypothesis and identified topoisomerase 2β as the primary molecular target for cardioprotection. This review outlines current strategies for primary and secondary prevention of anthracycline-induced cardiotoxicity resulting from newly recognized molecular mechanisms and identifies knowledge gaps requiring further investigation.
['Vejpongsa|Pimprapa|P|', 'Yeh|Edward T H|ET|']
D018943:Anthracyclines D000903:Antibiotics, Antineoplastic D002986:Clinical Trials as Topic D004317:Doxorubicin D006331:Heart Diseases D006333:Heart Failure D006801:Humans D009369:Neoplasms D017382:Reactive Oxygen Species
chemotherapy cancer cardioprotection cardiomyopathy doxorubicin heart failure